132
Galectin-9 Targeting Monoclonal Antibody for Solid Tumours
QIMR
Antibody
Oncology
Hit To Lead or Lead Optimization
• To decreases the secretion and production of proinflammatory cytokines, increases the secretion and production of anti-inflammatory cytokines, and decreases surface expression of stimulatory molecules.
• Immune therapy has great potential for the treatment of autoimmune disease. Galectin-9 (GAL9) is an S-type lectin beta-galacto sidebinding protein with N- and C- terminal carbohydrate-binding domains connected by a linker peptide. GAL9 has been implicated in modulating cell-cell and cell-matrix interactions. GAL9 has been shown to bind soluble PD-L2, and at least some of the immunological effects of PD-L2 have been suggested to be mediated through binding of multimeric PD-L2 to GAL9, rather than through PD-1. However, mechanisms by which GAL9 and PD-L2 impact immune effector function are not yet fully characterized.
• Galectin-9 (GAL9) modulates anti-tumour immune cell activity via enhancing co-stimulatory signaling. Galectin-9 is overexpressed in the TME of solid tumours and associated with improved survival in some indications. Developing mAbs to enhance Galectin-9 mediated colocalization of co-stimulatory molecules.
WO2020237320A1
